Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Better Therapeutics's share price for the quarter that ended in Sep. 2023 was $0.366. Better Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Sep. 2023 was 40.58 Mil. Therefore, Better Therapeutics's market cap for the quarter that ended in Sep. 2023 was $14.85 Mil.
Better Therapeutics's quarterly market cap
increased
from Mar. 2023 ($16.70 Mil) to Jun. 2023 ($34.34 Mil) but then
declined
from Jun. 2023 ($34.34 Mil) to Sep. 2023 ($14.85 Mil).
Better Therapeutics's annual market cap
increased
from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($109.75 Mil) but then
declined
from Dec. 2021 ($109.75 Mil) to Dec. 2022 ($26.36 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Better Therapeutics's Enterprise Value for Today is $0.00 Mil.
Better Therapeutics (OTCPK:BTTX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Better Therapeutics Market Cap Related Terms
Better Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Better Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Better Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Better Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Better Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Better Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Better Therapeutics's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Better Therapeutics (BTTX) has a Market Cap of $0.00 Mil as of Jul. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Better Therapeutics and its competitors.
Is Better Therapeutics' Market Cap too high?
Better Therapeutics' current Market Cap is $0.00 Mil.
How does Better Therapeutics' Market Cap compare to CYCN and CELZ?
Better Therapeutics' Market Cap of $0.00 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 119.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.04, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Better Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 119.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Better Therapeutics's current Market Cap is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Better Therapeutics stock overvalued right now?
Better Therapeutics (BTTX) has a current Market Cap of $0.00 Mil. The current Market Cap is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Better Therapeutics (BTTX), the current Market Cap is $0.00 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTTX has been successfully added to your 